Improvements in FEV1 and symptoms in poorly-reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Lung function and symptom improvements with fluticasone propionate/salmeterol 250/50 and ipratropium/albuterol in patients with mild to moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
Survival in COPD patients after regular use of fluticasone propionate and salmeterol Source: Eur Respir J 2003; 21: 559-560 Year: 2003
Improvement of dyspnoea following of six months treatment with tiotropium but not with salmeterol in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 26s Year: 2001
Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice Source: Eur Respir J 2001; 18: Suppl. 33, 348s Year: 2001
Lung function and symptom improvement with fluticasone/salmeterol and ipratropium/albuterol in albuterol responsive and non-responsive COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 89s Year: 2004
Effect of discontinuation of inhaled fluticasone propionate on exacerbations in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 183s Year: 2001
Improvement in dyspnea with fluticasone/salmeterol compared with salmeterol or ipratropium in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004
Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD Source: Eur Respir J 2004; 24: Suppl. 48, 513s Year: 2004
Asthma total costs reduction and clinical improvement after inhaled steroid shift to fluticasone propionate during 1 year in patients with moderate to severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 56s Year: 2002
Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006
Acute effect of formoterol, salmeterol, albuterol, oxitropium bromide and placebo on FEV1, inspiratory capacity and dyspnoea in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 380s Year: 2001
Sustained FEV1 increases in COPD patients induced by salmeterol 50 mcg twice daily via the diskus inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002
Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006